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INTRODUCTION
Cardiovascular diseases remain the number one
cause of morbidity and mortality, both in the Western
world and developing countries and in men and women
alike.1 In 2005, the main cause of death in the USA due
to disease of the heart alone was more than of all neo-
plastic disease combined. It is expected that these
numbers will continue to increase in the coming decades
due to escalating proportions of obesity and the aging
population. In addition to cardiac disease, cerebrovas-
cular disease, diabetes, and hypertension result in
substantial morbidity and mortality. Therefore, cardio-
vascular diseases as a whole are killer number one in the
Western world, and will most likely remain to be so due
to adverse lifestyle changes, including unhealthy diets
and lack of exercise.
Myocardial infarction (MI) is the number one car-
diac disease and often strikes the individual
unexpectedly; in 50% of cases MI is the first symptom of
coronary atherosclerosis. Atherosclerosis is character-
ized by a chronic inflammatory response resulting in the
formation of multiple plaques in the lumen of the artery.
This can happen gradually as a result of progressive
plaque growth or suddenly as a result of plaque rupture
and, subsequently, thrombosis causing acute MI (AMI).
The improvements in treatment of AMI have
resulted in better survival and a decrease in the acute
complications of MI, such as acute congestive heart
failure (CHF), myocardial rupture, arrhythmias, and
conduction system disorders. However, with more
patients surviving the initial stage of AMI, the devel-
opment of late complications of AMI become a more
prominent health care problem.
The development of left ventricular dilatation and
loss of pump function in the years following the acute
myocardial injury, induced by the formation of the scar,
and the impact of the local loss of function on pressure
and tensile forces in the noninfarcted left ventricle, are
the subject of intense research. Many trials in this area
have convincingly shown that inhibition of the renin–
angiotensin system, through either ACE inhibitors and/
or angiotensin receptor 1 blockers, preserve cardiac
function and decrease mortality post MI.2 In addition,
intervention in mineralocorticoid signaling has proven to
preserve cardiac function and decrease mortality sig-
nificantly.3,4 Despite these advances, still a substantial
fraction, about one-third of AMI patients, will develop
pump function disorders of the left ventricle in the long
run. The outcome of a relatively recent biomarker
known as NT-pro Brain Natriuretic Peptide (NT pro-
BNP), which is released by cardiomyocytes after the
occurrence of ventricular malfunction, has proven its
usefulness in diagnosing heart failure.5 Nevertheless, it
is hard to predict in which individual patient CHF will
occur. Therefore, there is still a lot to be learned and to
be gained from research in cardiac infarct healing and
adverse left ventricular remodeling.
An upcoming diagnostic tool in analyzing the risk of
cardiovascular disease in patients is cardiac imaging.6 The
capability to visualize macroscopic cardiovascular struc-
tures and the anatomical and functional consequences of
cardiac diseases in patients has made a remarkable pro-
gression in the last decades. The development of coronary
angiography (CAG), echocardiography, magnetic reso-
nance imaging (MRI), and multi-detector CT (MDCT) has
improved our approach in diagnosing cardiovascular dis-
ease such as atherosclerosis or left ventricular function.
However, most of these imaging technologies are able to
diagnose the end stage of the disease, rather than the
beginning of the disease or even pre-disease states. The
next frontier in imaging will be the development of the
capability to image fundamental biological or molecular
changes which cause cardiovascular disease and are able to
predict disease outcome at an early stage. For this purpose,
imaging tools other than those mentioned above have to be
developed.7
Imaging techniques, which visualize the fundamental
biological characteristics resulting in cardiovascular dis-
ease, may provide the potential to predict cardiovascular
catastrophe as an early diagnostic tool.8 With the intro-
duction of molecular imaging, the opportunities to detect
changes in biology of infarcted hearts and, therefore,
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cardiac remodeling in vivo have increased significantly in
the past decade.
It can be hypothesized that the ability to visualize
interstitial processes on a molecular level, which pre-
cede the geometric and functional deterioration of the
left ventricle, should help to better predict the likelihood
and rate of remodeling and development of HF.9 Several
key biological features provide attractive targets for
molecular imaging in heart failure. First, the develop-
ment of imaging techniques visualizing the biological
events of angiogenesis and fibrogenesis, which are
considered key processes in myocardial scar formation
and left ventricular remodeling, may provide attractive
targets for the identification of patients at risk to develop
a failing heart. The use of agents targeted to the integrin
alpha v beta 3 (avB3) may offer diagnostic means to
achieve this goal.
Second, apoptosis, a form of programmed cell death
(PCD), has shown to play a key role in the process of
gradual loss of pump function in animal models of heart
failure, caused by different triggers. Therefore, imaging
apoptosis may provide a means to identify hearts that are
in the process of substantial cardiomyocyte loss and
subsequent loss of pump function. The use of radiola-
beled Annexin A5, which shows strong affinity to
apoptotic cells which have externalized phosphatidyl
serine, may provide an opportunity to develop such a
heart failure imaging diagnostic test.
Finally, it is well known that the activation of the
renin–angiotensin axis plays a pivotal role in the
development of heart failure post AMI. Therefore,
imaging of the different components of renin–angio-
tensin neurohumoral axis may give an additional
diagnostic tool for better identification of patients prone
to develop heart failure. This brief review will discuss
the recent progresses made in molecular cardiac imag-
ing, focusing mainly on the achievements made in avB3
imaging, apoptosis imaging, and imaging of the activa-
tion of the renin–angiotensin system.
AVB3 IMAGING AS A TOOL TO IDENTIFY POST
MI REMODELING
As described above, early diagnosis of the impact of
the infarct on adverse left ventricular remodeling in the
individual patient could prevent worsening of left ven-
tricular pump function by adapting treatment to the
individual needs and risks. Two main events that occur
in the infarcted area are angiogenesis and collagen
deposition. The formation of new blood vessels is cru-
cial for infarct healing, and is induced by several factors,
such as basic fibroblast growth factor (bFGF) and vas-
cular endothelial growth factor (VEGF).10 Among other
regulators of angiogenesis, the avB3 integrin has been
identified as a critical angiogenic modulator. Angiogenic
vessels display increased expression of this critical
integrin.11 This discovery led to the development of
imaging tools to detect tumor angiogenesis with the use
of avB3 integrin targeting agents.12,13
Figure 1. Short axis imaging data 3 weeks after induction of LAD infarction in a dog model. At the site of the
perfusion defect (left panel), uptake of the indium-labeled avB3 RP 748 targeting tracer was observed (middle panel).
Left panel shows the fusion data.
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In addition, imaging of avB3 integrin has been used
to noninvasively visualize angiogenesis in infarcted
hearts. Meoli et al used indium-111-RP748 (111In-
RP748), a radiolabeled avB3 targeted compound, to
image angiogenesis in infarcted canine hearts with
SPECT imaging.14 111In-RP748 uptake peaked at
1 week after reperfusion and was associated with avB3
integrin expression on endothelial and vascular smooth
muscle cells. In addition, they used the same targeting
agent in infarcted dog hearts which showed uptake of
111In-RP748 at the side of the perfusion defect using
SPECT imaging (Figure 1).
Recently, 18F-Galacto-RGD, a PET tracer targeting
specifically avB3 integrin expression, has been intro-
duced.15 Higuchi et al used this tracer to monitor avB3
integrin expression in rat hearts after ischemia/
reperfusion, and reported results comparable with
111In-RP748 imaging.16 Clinical use of the 18F-Galacto-
RGD PET tracer in a patient with MI was reported
shortly.17
Apart from its crucial involvement in angiogenesis,
avB3 integrin also has been linked to the development of
fibrosis,18,19 which led our group to evaluate whether








































Figure 2. A, Nuclear imaging showed that no uptake was seen of the avB3 targeted tracer was seen
in normal controls and in mice with infarcted hearts injected with a scrambled variant of the
targeting peptide. Uptake of the tracer peaked at 2 weeks post MI, and decreased gradually at
4 weeks and 12 weeks, respectively. B, The in vivo imaging data are confirmed by quantitative
measurement (% injected dose per gram) in the infarct zone (left panel). In the mid sections and
base sections no significant uptake of the tracer was observed.
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fibrogenesis in the infarcted heart.20 MI was induced in
mice, which received a 99mTc-labeled Cy5.5-RGD
imaging peptide (CRIP) intravenously for microSPECT
imaging of integrin at 2, 4, and 12 weeks after MI
(Figure 2).
The uptake of CRIP was most pronounced in the
infarcted area, and peaked at 2 weeks after MI.
Immunological analysis linked CRIP uptake to myofi-
broblasts, and CRIP uptake paralleled with the
production of newly formed collagen, with a yellow/
green birefringence. In addition, several mice were
treated with antagonists of the renin–angiotensin sys-
tem, which is known to be involved in pathological
myocardial remodeling. Interestingly, mice treated with
captopril or with captopril and losartan displayed sig-
nificantly reduced uptake of the CRIP (Figure 3). Thus,
apart from the potential value of radiolabeled CRIP in
visualizing collagen formation, it may also fulfill the
need for a surrogate endpoint marker for therapeutic
interventions.
In conclusion, imaging of avB3 integrin has the




























Figure 3. A, The effect of treatment with captopril and/or losartan post MI. In the treated groups,
less uptake of the avB3 targeting tracer was observed using captopril and an even more extensive
reduction when the treatment of captopril was combined with losartan. B, The imaging data were
confirmed by quantitative measurement (% injected dose per gram).
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and thereby will help to optimize medical treatment.
However, prospective clinical trials are needed to
investigate whether the potential of integrin imaging
translate into clinically useful diagnostic tests.
APOPTOSIS AS A TARGET FOR MOLECULAR
IMAGING IN CHF
Apoptosis plays a key role in the process of deg-
radation of cardiomyocytes resulting in ventricular
dysfunction.21-24 Research in animal models of CHF has
demonstrated that interference in apoptosis pathways
delays the ongoing process of pump function disorders
resulting in heart failure.25
One of the main biochemical characteristics of
apoptosis is caspase 3 activation. The process of acti-
vation of caspase 3, an apoptosis-related cysteine
protease, begins with the release of cytochrome C into
the cytoplasmic area, mainly caused by oxidative stress
and cytokinemia. Caspases have numerous substrates,
including contractile proteins, such as troponin-T. In
addition, in most cells, caspase activation results in
Figure 4. Uptake of 99mTc-labeled Annexin A5 in advanced cardiomyopathy. A, Patient with dilated cardiomyopathy (DCMP) and
reduced left ventricular function showing focal uptake in the anterolateral region of the heart. B, Patient with DCMP in acute heart
failure showing global uptake. C, DCMP in a patient with no symptoms of heart failure, notice no uptake is present. In D, relative of
DCMP patient, absence of uptake of 99mTc-labeled Annexin A5 (adapted from Kietselaer et al30).
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activation of DNA fragmentation enzymes. However, it
is thought that the activation of DNA fragmentation
enzymes in heart muscle cells is compensated for by
different antiapoptotic pathways. The consequence of
apoptosis activation in cardiomyocytes is that these cells
become dysfunctional, but still survive due to the pres-
ervation of DNA. This means that restoration of a
healthy environment could potentially restore individual
cardiomyocyte function. Another consequence of cas-
pase 3 activation is that it results in alterations in
phospholipid distribution in the sarcolemmal lipid
bilayer, causing revelation of phosphatidyl serine (PS) to
the surface of the cell membrane.26,27 Theoretically, the
extent of PS externalization reveals an indication of the
degree of apoptosis in the heart. Accordingly, it is
plausible that PS can be a used as a target to detect
activated cell death in heart failure. The detection of PS
exposure has been proven extensively by radionuclide
imaging using 99mTc-labeled Annexin A5.28,29
Kietselaer et al recently demonstrated the feasi-
bility of Annexin A5 imaging to reveal PCD in a small
group of patients with recently diagnosed advanced
heart failure. Imaging of 99mTc-labeled Annexin A5
was performed using a SPECT in nine CHF patients
with advanced nonischemic cardiomyopathy (hyper-
trophic, N = 1, dilated, N = 8). To include a similar
genetic background as the hypertrophic cardiomyopa-
thy patient, the same imaging procedure was performed
on two relatives who did not suffer from CHF. Left
ventricular uptake of Annexin 5 was demonstrated
focal, multifocal, or diffuse in a total of five patients.30
All patients in whom 99mTc-labeled Annexin A5
uptake was present in the left ventricle were diagnosed
with a significant decrease of left ventricular function
as demonstrated by follow-up echocardiography 1 year
later (Figure 4).
The five patients who demonstrated no uptake of
Annexin A5 remained in a stable clinical state or even
showed improvement of left ventricular function (Fig-
ure 5). In line with the data in animal models of CHF,
these data suggest that Annexin A5 uptake is related to
dysfunction of the left ventricle. Annexin A5 may pro-
vide the potential to become a useful imaging tool to
identify patients with active apoptosis in the myocar-
dium, which most likely indicates a transition to overt
heart failure. The question remains what Annexin A5
binding into the myocardium indicates, since it was
suggested that cardiomyocytes activate caspases during
apoptosis, but that DNAses are not activated, resulting in
the concept of apoptosis interruptus.
Figure 6 shows a possible explanation for uptake of
99mTc-labeled Annexin A5 after apoptosis is stimulated.
The revelation of PS is a response of caspase 3 activa-
tion. As mentioned above, different antiapoptotic
Figure 5. Differences in left ventricular ejection fraction after
1 year follow-up in CDMP patients with uptake of Annexin A5
and no uptake of Annexin A5 on SPECT (adapted from
Kietselaer et al30.
Figure 6. The concept of PS externalization in heart failure.
Cytokine and oxidative stress (reactive oxygen species)
inducing release of cytochrome c out of the mitochondria
lead to caspase 3 activation. This results in cytoplasmic
proteolysis and DNA fragmentation, ultimately leading to
apoptosis. The increase of BC12- and XIAP proteins and the
loss of DNAses prevent the so-called apoptosis interruptus and
activate caspase 3.
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pathways, preventing the degradation of DNA, com-
pensate for the activation of DNA fragmentation
enzymes in heart muscle cells. It is assumed that the
quantity of PS, which manifests externally, is an indi-
cation of the amount of activated of caspase 3.
Therefore, it is believed that Annexin 5 uptake not
necessarily indicates loss of cardiomyocytes, but is a
reflection of the activation level of caspase-3.
THE AT-1 RECEPTOR AS A TARGET
FOR MOLECULAR IMAGING IN CHF
The essential role of the renin–angiotensin system
in ventricular remodeling following AMI has been
established in many experimental and clinical studies.
Rather than circulating renin–angiotensin levels, it
believed that myocardial upregulation of angiotensin
converting enzyme, angiotensin II, and its receptors
determine the likelihood of ventricular remodeling.31,32
In an experimental study in mice, it was shown that
transgenic mice with deficient angiotensin II type 1
receptor expression revealed negligible remodeling post
MI. Moreover, a lower expression of fibrosis and
transforming growth factor (TGF-B1) was demon-
strated.31 These insights from experimental models have
been translated to clinical studies showing that patients
with CHF patients using angiotensin receptor block-
ers33,34 and/or ACE-inhibitors35-37 have substantially
improved survival. It has been suggested that maximi-
zation of antiangiotensin therapy, including increase in
ACE-inhibitor dose or addition of ARB over ACE-
inhibitor therapy, could further reduce morbidity33,38
and mortality39 in HF. It is, therefore, imaginable that
accurate assessment of myocardial angiotensin receptor
expression could potentially guide optimization of an-
tiangiotensin therapy. Nowadays, diagnostic imaging of
HF is focused on geometric and structural cardiac
imaging.40,41
As mentioned above, it is well known that inhibition
of the renin–angiotensin system, through either ACE
inhibitors and/or angiotensin receptor 1 blockers, pre-
serve cardiac function and decrease mortality post MI.2
Verjans et al investigated the potential of angiotensin
receptor II type 1 imaging in an animal model of post MI
left ventricular remodeling.42 A fluorescent label was
marked to an angiotensin peptide analogue (APA),
which traced angiotensin type 1 and 2 receptors for
imaging purposes. The data from the study showed
distinct uptake of the fluorescent tracer in the infarct and
border zone of the mouse hearts between 1 and 6 weeks
post MI (Figure 7).
At time point of 12 weeks, the uptake was markedly
reduced. Immunohistochemical analysis and 2-photon
microscopy showed co-localization of the tracer with
both myofibroblasts and collagen. No uptake of the
fluorescent tracer was observed in cardiomyocytes.
Upregulation of the AT1 receptor on myofibroblasts
allows for growth factor (such as angiotensin-II)-
induced proliferation and collagen production, which is
believed to contribute to healing and the remodeling
process following MI.43,44
The same research group created a radiolabeled
imaging tracer of a well-known angiotensin II antagonist
named Losartan. With the use of this analogue, SPECT-
CT imaging was performed after left ventricular func-
tion was evaluated by echocardiography. These imaging
studies showed that uptake of the radiolabeled Losartan
product co-localized to the infarct area on SPECT-CT
imaging, and that the uptake of the radiolabeled product
in the infarct area was 2.4-fold higher as compared to
control hearts (Figure 8). Together, these data demon-
strate the feasibility of in vivo imaging through targeting
of angiotensin receptors in an experimental HF model.
Furthermore, the data showed that upregulation of
angiotensin receptor preceded the development of left
ventricular remodeling, as detected by echocardiogra-
phy. Currently, significant emphasis is being placed on
the recognition of stage A and B HF patients as a
strategy of prevention of more advanced HF.45
Accordingly, development of a technology that predicts
occurrence of cardiac remodeling, such as AT-1 receptor
imaging, is of crucial importance, especially since the
clinical practice nowadays allows diagnosis of HF only
after the left ventricle has undergone adverse
remodeling.
This concept is further emphasized by the recent
demonstration of another strategy for imaging renin–
angiotensin axis with the use of radiolabeled benzoyl
lisinopril. Dilsizian et al incubated short-axis myocardial
slices explanted from patients undergoing cardiac
transplantation for end-stage ischemic cardiomyopathy
with F-18 fluoro-benzoyl lisinopril.46 There was specific
binding of radiotracer to ACE; mean binding was
6.6 ± 5.2 compared with 3.4 ± 2.5 luminescence/mm2
in segments pre-incubated with cold lisinopril
(P \ 0.0001). Furthermore, mean radiotracer binding
was 6.3 ± 4.5 in infarcted, 7.6 ± 4.7 in peri-infarcted,
and 5.0 ± 1.0 luminescence/mm2 remote noninfarcted
(P \ 0.02) segments. Together, these imaging studies
demonstrate that activation of the renin–angiotensin
system can be visualized using molecular imaging
technology. Both studies also showed that the compo-
nents of the tissue renin–angiotensin cascade are
upregulated only about 2- to 3-fold. It remains unclear
whether such relatively small difference between
remodeling cardiac tissue and control hearts could pro-
vide a clinically robust diagnostic strategy for imaging
targeted to ATR and/or ACE.
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Figure 7. A, Imaging data show the uptake of the fluorescent AT1 receptor-targeted tracer at
different time points after MI. The uptake peaks at 1 week post AMI, and then gradually decreases
over time. In B, the concomitant echocardiographic data are shown, indicating a clear increase in
LV end diastolic diameter.
Figure 8. In A, the control mouse does not show uptake of the technetium-labeled losartan product on SPECT-CT
imaging. In B, in a mouse 3 week post MI clear uptake of the tracer can be seen on SPECT-CT imaging. In C,
quantitative analysis (% injected dose per gram) shows a 2.4-fold uptake of the tracer in the infarct area. In the border
zone and remote zone no significant differences were seen.
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OUTLOOK
Based on the preclinical and clinical data obtained
in molecular imaging of adverse left ventricular
remodeling, the current outlook for the development of
such an imaging technology is promising. For both the
imaging of avB3 integrin and imaging of phosphatidyl
serine expression as a reflection of caspase 3 activa-
tion, the preliminary data provide a sufficient basis for
the design and execution of novel studies. For imaging
of the components of the renin–angiotensin system, the
extent of uptake may be insufficient to form a basis for
clinical applications. However, before one of these
technologies could be adopted as diagnostic tests for
routine clinical use, large clinical studies need to be
conducted to address key questions. For instance, it is
still unknown whether the uptake of avB3 targeting
tracers is robust enough to uncover patients that are at
the brink of developing adverse remodeling post MI. In
addition, it remains to be seen whether the extent of
the uptake of the tracer can be modulated by treatment
with different regimes of CHF treating compounds.
Studies focused on addressing these questions are
under way.
For imaging phosphatidyl serine exposure in the
heart using Annexin A5, as a reflection of caspase-3
activation, the outlook depends largely on the avail-
ability of clinically graded Annexin A5 imaging
diagnostic kits. With the availability of clinical Annexin
A5 imaging kits, studies could be designed to further
explore the predictive value of Annexin A5 in patients
with failing hearts and to study the effect of therapeutic
interventions.
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